Course Information

Release date: November 3, 2026
Expiration date: November 3, 2027
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC. (ACCME Credit)
This activity is jointly provided by Global Education Group (Global) and Integrity CE, LLC. (ANCC, AANP, & ACPE Credit)

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Insmed, Inc.

PROGRAM OVERVIEW

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is often underrecognized, leading to delayed diagnosis and treatment. This activity reviews emerging approaches to identifying PH-ILD, distinguishing it from other pulmonary hypertension subtypes, and applying evidence-based management strategies. Participants will explore evolving disease biology, recent therapeutic advances, and practical strategies to support earlier diagnosis, appropriate referral, and individualized treatment decisions across the disease continuum.

Learning Objectives

TARGET AUDIENCE

This educational activity is designed for pulmonologists, cardiologists, radiologists, primary care physicians, nurse practitioners, physician associates, and other clinicians involved in managing care for patients with pulmonary vascular disease.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Differentiate PH-ILD from other PH subtypes and progressive ILDs, focusing on early evaluation and assessment approaches
Evaluate clinical trial findings from recently approved treatments for PH-ILD and PPF
Integrate new and anticipated therapies for PH-ILD based on disease severity, comorbid ILD phenotype, and patient-centered goals

Faculty Information and Disclosures

MODERATOR

Sheila Weaver, DO

Professor of Clinical Medicine

Department of Thoracic Medicine and Surgery

Lewis Katz School of Medicine

Temple University Hospital

Philadelphia, Pennsylvania

FACULTY PANEL

Shameek Gayen, MD

Assistant Professor

Associate Program Director

Pulmonary and Critical Care Fellowship

Department of Thoracic Medicine and Surgery

Lewis Katz School of Medicine

Temple University

Philadelphia, Pennsylvania

Lijo C. Illipparambil, MS, MD

Assistant Professor, Clinical Thoracic Medicine and Surgery

Department of Thoracic Medicine and Surgery

Lewis Katz School of Medicine

Temple University

Philadelphia, Pennsylvania

Parth Rali, MD, FCCP, FAPSR

Professor of Medicine

Director, PERT Program and Anti Coagulation Stewardship Program

Temple Lung Pulmonary Vascular Disease Program

Division of Thoracic Medicine and Surgery

Lewis Katz School of Medicine

Temple University Hospital

Philadelphia, Pennsylvania

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC and Global require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Shameek Gayen, MD does not have any financial relationships or relationships to products or devices with ineligible companies.  

Lijo C. Illipparambil, MS, MD

Advisor: LungPacer  

Parth Rali, MD, FCCP, FAPSR

Advisory Board: Liquidia, UT

Consultant: AIDOC, Penumbra, Stryker, Viz.AI

Speaker: Merck

Sheila Weaver, DO does not have any financial relationships or relationships to products or devices with ineligible companies.  

The Integrity CE, LLC and Global planners and managers do not have any relevant financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of November 3, 2026 to November 3, 2027, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.

PHYSICIAN ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Integrity CE, LLC. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurse Contact Hours Designation

Global Education Group designates this continuing education activity for 0.75 contact hour including 0.0 pharmacotherapeutic contact hour(s).

Pharmacist Credit Designation

Global Education Group designates this continuing education activity for 0.75 contact hour (0.075 CEUs). (Universal Activity Number - JA0007169-9999-26-016-H01-P). This is a knowledge-based activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners^® (AANP) through the joint providership of Global Education Group and Integrity CE, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.75 contact hour (which includes 0.0 hours of pharmacology).

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

For information about the Joint Accreditation (ANCC and ACPE credit) or approval (AANP) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC and Global do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: November 3, 2026Expiration date: November 3, 2027Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

DISCLOSURE OF COMMERCIAL SUPPORT

PROGRAM OVERVIEW

TARGET AUDIENCE

LEARNING OBJECTIVES

MODERATOR

FACULTY PANEL

DISCLOSURE OF CONFLICTS OF INTEREST

DIRECTIONS TO LEARNER

PHYSICIAN ACCREDITATION STATEMENT

JOINT ACCREDITATION STATEMENT

CONTACT INFORMATION

DISCLOSURE OF UNLABELED USE

MEDIA

PRIVACY POLICY

MINIMUM SYSTEM REQUIREMENTS

DISCLAIMER

Release date: November 3, 2026
Expiration date: November 3, 2027
Estimated time to complete activity: 45 minutes

PH-ILD and Progressive Pulmonary Fibrosis: Advancing Diagnosis and Therapeutic Precision